Monitor for potential follow-on selling or absence of buying ahead of next earnings. The divergence between cash selling and non-cash grants may signal lack of conviction despite equity compensation.
VIR drugs
VIR drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 23 $7.43entry
- T+1 · 9mo ago +27.73%α +26.99% · $9.49
- T+5 · 9mo ago +25.71%α +25.09% · $9.34
- T+20 · 8mo ago +18.98%α +22.92% · $8.84
- T+60 · 6mo ago +18.04%α +9.78% · $8.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple C-suite executives at Vir Biotechnology, including the CEO, CFO, and General Counsel, conducted open-market share sales over the past week, totaling $404,942 in sales proceeds. These transactions coincide with a routine grant of stock awards worth $0 in value. The selling represents modest insider divestment by top executives.
Key Financial Metrics
Key Facts
- CEO Marianne De Backer sold 33,801 shares for $282,614 in open-market transactions.
- CFO Jason O'Byrne and General Counsel Vanina de Verneuil each sold 2,089 and 21,262 shares, respectively, netting $15,569 and $197,375 total.
- Five C-suite insiders sold shares in open market, aggregating $404,942 in total proceeds.
- All sales occurred between $7.45 and $9.82 per share, with higher prices on later dates.
- On the same day as the sales began, the company granted non-cash stock awards totaling 420,000 shares to these insiders, which do not represent economic buying interest.
Financial Impact
$404,942 in open-market insider selling over 7 days
Risk Factors
- Perception of insider pessimism, especially from CEO and CFO selling material amounts.
- Potential downward pressure on shares if selling continues or is interpreted as negative signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (13 trades, 7d window) | cluster-VIR-1772142904713 |
Track record
36 reports on VIR
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers